Humanetics announced that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM’s assets related to the manufacture of the active pharmaceutical ingredient (API) in BIO 300, a clinical stage drug being developed by Humanetics for oncology and biodefense applications.
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the closing of a $105 million Series C equity financing.
Ligand Pharmaceuticals announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash. Icagen will also be entitled to receive up to an additional $25 million of cash payments based on certain revenue achievements.
Valeritas Holdings announced an agreement to sell substantially all of the business to Zealand Pharma, a Denmark-based biotechnology company.
Roche’s investigational medicine gantenerumab has failed to achieve its primary endpoint in the Phase II/III Alzheimer’s disease (AD) trial.
Azafaros B.V. announced today the successful closing of its Series A financing round raising EUR 25 million (approximately USD 28 million).
X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEX) drug discovery platform to the generation of novel small molecule therapeutics, announced a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment of allergies.
Genprex, a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, provides a clinical update and focus for its Oncoprex immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).
Aimmune Therapeutic has secured exclusive worldwide rights to Xencor’s XmAb 7195 for the development of next-generation food allergy treatments.
Regeneron Pharmaceuticals has expanded its collaboration with the US Department of Health and Human Services (HHS) to develop antibody treatments for novel coronavirus (2019-nCoV).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.